AI Article Synopsis
Article Abstract
Abstract Carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions, are difficult to treat and generally carry a poor prognosis. The purpose of this study was two-fold; first, to determine the prognosis for dogs with carcinomatosis, sarcomatosis, or mesothelioma, with or without malignant effusions; second, to evaluate the safety and efficacy of treatment with intracavitary (IC) carboplatin and mitoxantrone in dogs with these syndromes. Nineteen dogs were evaluated. Seven were untreated and 12 were treated with IC chemotherapy (mitoxantrone and/or carboplatin), and multiple factors were analysed for significance with respect to survival time. The median survival time (MST) for untreated dogs was 25 days, whereas the MST for treated dogs was 332 days (Log Rank, P < 0.0001). Treatment with IC chemotherapy was well tolerated. This study suggests that IC chemotherapy with mitoxantrone and/or carboplatin is an effective treatment for dogs with carcinomatosis, sarcomatosis or mesothelioma, with or without malignant effusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1476-5810.2005.00075.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Review of Imaging Peritoneal Disease and Treatment.
Can Assoc Radiol J
December 2024
Abdominal Division, Joint Department of Medical Imaging, Toronto, ON, Canada.
Article Synopsis
- Peritoneal disease is divided into benign and malignant categories, with malignant cases further classified into primary and secondary types, including conditions like peritoneal mesothelioma and peritoneal carcinomatosis.
- Differentiating between benign and malignant peritoneal conditions is crucial, as this determines the course of treatment and helps avoid unnecessary procedures.
- For patients with secondary malignant diseases like peritoneal carcinomatosis, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a chance for cure, and radiologists play a key role in assessing disease extent and potential surgical issues.
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis.
Cancers (Basel)
August 2024
Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
(1) Background: Cytoreductive surgery (CRS) with HIPEC is considered the standard of care for selected patients with peritoneal carcinomatosis, but evidence-based treatment recommendations for the therapy of peritoneal sarcomatosis are scarce. (2) Methods: We retrospectively analyzed all adult patients treated with CRS and HIPEC for peritoneal sarcomatosis between 2017 and 2024. (3) Results: Ten patients with a median age of 46.
View Article and Find Full Text PDFIbero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.
Cancers (Basel)
July 2024
Hepatobiliary Surgery and Liver Transplant Unit, Gregorio Marañón University Hospital, 28007 Madrid, Spain.
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis.
View Article and Find Full Text PDFRadical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal sarcomatosis: Results from a reference center and considerations based on current evidence.
Cir Esp (Engl Ed)
August 2024
Sección Tumores Mesenquimales y Sarcomas de la Asociación Española de Cirujanos (AEC), Madrid, Spain; Servicio de Cirugía General y del Aparato Digestivo, CSUR de Sarcomas y Tumores Músculo-Esqueléticos, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Introduction: Peritoneal sarcomatosis is a rare disease, with multiple histological origins and poor overall prognosis. The option of radical cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is controversial. The results of a surgical team experienced in these procedures are analyzed and discussed based on the available evidence.
View Article and Find Full Text PDFPrimary and secondary tumors of the peritoneum: key imaging features and differential diagnosis with surgical and pathological correlation.
Insights Imaging
July 2023
Department of Radiology, Hospital Clinic, Barcelona, Spain.
Peritoneal malignancies represent a diagnostic challenge for abdominal radiologists, oncologists, surgeons and pathologists in multidisciplinary teams, who must address their differential diagnosis, staging and treatment. In this article, we explain the pathophysiology of these processes and lay out the role of different imaging techniques in their evaluation. Then, we review the clinical and epidemiological aspects, the main radiological features and the therapeutic approaches for each primary and secondary peritoneal neoplasm, with surgical and pathological correlation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!